Clinical trials for Endocrinology/Metabolism specialty

  • Status:  Currently enrolling


    We hypothesize that the orally administered drug, bexagliflozin, will improve glycemic control in poorly regulated diabetic cats. The primary objective of this study is to determine if mean blood sugar and fructosamine concentrations decrease by ≥10% with administration of bexagliflozin over a two week period. The secondary objective is to determine if bexagliflozin is well tolerated by poorly regulated diabetic cats.

    Inclusion Criteria:

    Cats with unregulated diabetes mellitus based on history of persistent hyperglycemia(>250 mg/dl) and appropriate clinical signs, including polyuria, polydipsia and weight loss

    Exclusion Criteria:

    Cats with documented azotemia, elevated bilirubin, ALT >2.5x the upper limit of normal, diabetic ketoacidosis, urinary tract infection, use of corticosteroids within the past 8 weeks, heart disease requiring medication and uncontrolled hyperthyroidism based on preliminary laboratory testing

    Client benefits:

    The study will cover the costs of blood work and urine tests required for the study, blood pressure measurement, day boarding as well as the cost of the medication.  We will be teaching you how to monitor your cat's blood glucose levels at home with a hand held glucometer that will be loaned from our hospital for the duration of the study.

    Contact information:

    For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: clinicaltrials@tufts.edu